|
Malignant neoplasm of breast
|
0.330 |
Biomarker
|
disease |
BEFREE |
While high mRNA expression of CUL2, CUL4B, and CUL5 were correlated with better survival for breast cancers.The associated results suggested that some Cullin members could serve as new predictive prognostic indicators for breast cancer.
|
31374029 |
2019 |
|
Breast Carcinoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
While high mRNA expression of CUL2, CUL4B, and CUL5 were correlated with better survival for breast cancers.The associated results suggested that some Cullin members could serve as new predictive prognostic indicators for breast cancer.
|
31374029 |
2019 |
|
Malignant neoplasm of breast
|
0.330 |
Therapeutic
|
disease |
CTD_human |
CMV vector and VACM-1 cDNA stably transfected T47D breast cancer-derived cells were treated with resveratrol and cell growth and VACM-1 protein concentrations were measured.
|
20949323 |
2011 |
|
Breast Carcinoma
|
0.330 |
Therapeutic
|
disease |
CTD_human |
CMV vector and VACM-1 cDNA stably transfected T47D breast cancer-derived cells were treated with resveratrol and cell growth and VACM-1 protein concentrations were measured.
|
20949323 |
2011 |
|
Malignant neoplasm of breast
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
T47D breast cancer cell growth is inhibited by expression of VACM-1, a cul-5 gene.
|
15184056 |
2004 |
|
Breast Carcinoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
T47D breast cancer cell growth is inhibited by expression of VACM-1, a cul-5 gene.
|
15184056 |
2004 |
|
Malignant neoplasm of breast
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
The cancer profiling array revealed that 82% (41/50) of the breast cancers demonstrated a decrease in CUL-5 expression versus the matched normal tissue.
|
14641918 |
2003 |
|
Breast Carcinoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
The purpose of this research was to determine if there is differential expression of CUL-5 in breast epithelial cells versus breast cancer cell lines, and normal human tissues versus human tumors.
|
14641918 |
2003 |
|
Mammary Neoplasms
|
0.310 |
Therapeutic
|
group |
CTD_human |
Resveratrol enhances anti-proliferative effect of VACM-1/cul5 in T47D cancer cells.
|
20949323 |
2011 |
|
Mammary Neoplasms
|
0.310 |
AlteredExpression
|
group |
BEFREE |
The decrease in CUL-5 expression in breast tumor tissue versus matched normal tissue supports the hypothesis that decreased expression of CUL-5 may play a role in breast tumorigenesis.
|
14641918 |
2003 |
|
Mammary Neoplasms, Human
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Resveratrol enhances anti-proliferative effect of VACM-1/cul5 in T47D cancer cells.
|
20949323 |
2011 |
|
Mammary Carcinoma, Human
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Resveratrol enhances anti-proliferative effect of VACM-1/cul5 in T47D cancer cells.
|
20949323 |
2011 |
|
Shock, Hemorrhagic
|
0.200 |
Biomarker
|
phenotype |
RGD |
This is the first report of cul-5 mRNA regulation by hemorrhagic shock.
|
12635525 |
2003 |
|
Rheumatoid Arthritis
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genetic influences on susceptibility to rheumatoid arthritis in African-Americans.
|
30423114 |
2019 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
In conclusion, our results indicate that CUL5 functions as a novel tumor suppressor with prognostic relevance in ccRCC and is critically involved in the maintenance of genome stability.
|
30631037 |
2019 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.030 |
Biomarker
|
disease |
BEFREE |
By comparing our results to the human immunodeficiency virus type 1 (HIV-1) Vif-CUL5 interaction surface (120IR121, a hydrophobic region that is localized in the zinc-binding motif), we suggest that the CUL5 interaction surface in the diverse HIV-1 and FIV Vifs is evolutionarily conserved, indicating a strong structural constraint.
|
29263270 |
2018 |
|
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Altered expression of cullin-5 (CUL5), a member of the cullin-RING E3 ubiquitin ligase family, has been implicated in a number of types of cancers including breast, cervical and hepatocellular cancers.
|
26847831 |
2016 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.030 |
Biomarker
|
disease |
BEFREE |
The human immunodeficiency virus type 1 (HIV-1)-encoded virion infectivity factor (Vif) is required to inactivate the host restriction factor APOBEC3 by engaging Cullin 5 (Cul5)-RING ubiquitin ligase (CRL5).
|
24390335 |
2014 |
|
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
These results indicate that miR-7 suppresses colony formation and causes cell cycle arrest via upregulation of CUL5, and it may function as a tumor suppressor in HCC.
|
24339204 |
2013 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.030 |
Biomarker
|
disease |
BEFREE |
We found that conjugation of NEDD8 to Cullin-5 by the NEDD8-conjugating enzyme UBE2F is required for HIV Vif-mediated degradation of the host restriction factor APOBEC3G (A3G).
|
23300442 |
2012 |
|
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Although decreased levels of VACM-1 mRNA detected in several cancers and cancer cell lines may explain the progression of cell growth, possible genetic and epigenetic changes in its sequence have not been analyzed.
|
21635549 |
2011 |
|
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
The cancer profiling array revealed that 82% (41/50) of the breast cancers demonstrated a decrease in CUL-5 expression versus the matched normal tissue.
|
14641918 |
2003 |
|
Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
The purpose of this research was to determine if there is differential expression of CUL-5 in breast epithelial cells versus breast cancer cell lines, and normal human tissues versus human tumors.
|
14641918 |
2003 |
|
HIV Infections
|
0.020 |
Biomarker
|
group |
BEFREE |
ARIH2 Is a Vif-Dependent Regulator of CUL5-Mediated APOBEC3G Degradation in HIV Infection.
|
31253590 |
2019 |
|
Malignant neoplasm of lung
|
0.020 |
Biomarker
|
disease |
BEFREE |
The CUL5 ubiquitin ligase complex mediates resistance to CDK9 and MCL1 inhibitors in lung cancer cells.
|
31294695 |
2019 |